Monaco Asset Management SAM Raises Stock Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV)

Monaco Asset Management SAM grew its holdings in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 35.0% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 135,000 shares of the company's stock after purchasing an additional 35,000 shares during the quarter. Monaco Asset Management SAM's holdings in Roivant Sciences were worth $1,597,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in ROIV. Gladius Capital Management LP purchased a new position in shares of Roivant Sciences during the third quarter worth approximately $35,000. US Bancorp DE raised its stake in shares of Roivant Sciences by 146.5% during the third quarter. US Bancorp DE now owns 3,278 shares of the company's stock worth $38,000 after acquiring an additional 1,948 shares in the last quarter. GAMMA Investing LLC raised its stake in shares of Roivant Sciences by 57.0% during the fourth quarter. GAMMA Investing LLC now owns 3,548 shares of the company's stock worth $42,000 after acquiring an additional 1,288 shares in the last quarter. PNC Financial Services Group Inc. raised its stake in shares of Roivant Sciences by 27.0% during the fourth quarter. PNC Financial Services Group Inc. now owns 7,079 shares of the company's stock worth $84,000 after acquiring an additional 1,507 shares in the last quarter. Finally, Quarry LP raised its stake in shares of Roivant Sciences by 50.0% during the third quarter. Quarry LP now owns 7,500 shares of the company's stock worth $87,000 after acquiring an additional 2,500 shares in the last quarter. Institutional investors own 64.76% of the company's stock.

Remove Ads

Insider Buying and Selling at Roivant Sciences

In other Roivant Sciences news, CAO Rakhi Kumar sold 227,500 shares of the company's stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $10.43, for a total value of $2,372,825.00. Following the completion of the transaction, the chief accounting officer now directly owns 163,264 shares in the company, valued at $1,702,843.52. This represents a 58.22 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Sciences Ltd. Roivant purchased 16,845,010 shares of the company's stock in a transaction on Monday, January 13th. The stock was acquired at an average price of $20.00 per share, with a total value of $336,900,200.00. Following the completion of the purchase, the director now directly owns 96,650,341 shares in the company, valued at $1,933,006,820. This trade represents a 21.11 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders sold a total of 2,388,170 shares of company stock worth $27,612,299 in the last three months. 7.90% of the stock is currently owned by company insiders.

Roivant Sciences Trading Down 1.3 %

NASDAQ:ROIV traded down $0.14 during mid-day trading on Tuesday, reaching $10.71. The company's stock had a trading volume of 3,638,684 shares, compared to its average volume of 5,497,675. The firm's fifty day moving average price is $10.80 and its two-hundred day moving average price is $11.49. The stock has a market cap of $7.64 billion, a P/E ratio of -71.40 and a beta of 1.26. Roivant Sciences Ltd. has a 12-month low of $9.76 and a 12-month high of $13.06.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last released its quarterly earnings results on Monday, February 10th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative return on equity of 14.05% and a negative net margin of 119.54%. Analysts predict that Roivant Sciences Ltd. will post -0.92 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the stock. HC Wainwright reissued a "buy" rating and set a $18.00 price target on shares of Roivant Sciences in a research note on Tuesday, February 11th. Cantor Fitzgerald upgraded shares of Roivant Sciences to a "strong-buy" rating in a report on Tuesday, March 4th. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of "Buy" and an average target price of $18.08.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.